Loseasonique is a contraceptive pill owned by Teva Branded Pharmaceutical. It contains two active ingredients, Ethinyl Estradiol and Levonorgestrel, and was first authorised for market use on October 24, 2008. The medication is manufactured in oral tablet form.
The generics of Loseasonique are anticipated to be released after December 5, 2028, when the last patent (US7855190) expires. This patent refers to methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration.
Loseasonique is used primarily for the prevention of pregnancy. The Ethinyl Estradiol and Levonorgestrel contained in the drug work together to prevent ovulation and estrogen withdrawal bleeding.
Loseasonique has a total of 3 drug patents. Of these, 2 have already expired - US7615545 and US7858605, both of which were focused on oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology. The remaining patent, US7855190, is set to expire on December 5, 2028. This means that the Loseasonique generic variant could be available after this date. Below are the details of the patent: